RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.22

Change

-0.13 (-1.22)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

+25.04 (+376.54%)

USD 2.80B
SH ProShares Short S&P500

+31.49 (+297.08%)

USD 0.99B
SOXS Direxion Daily Semiconductor B..

-1.27 (-6.32%)

USD 0.66B
PSQ ProShares Short QQQ

-0.58 (-1.52%)

USD 0.65B
SPXU ProShares UltraPro Short S&P50..

-0.52 (-2.33%)

USD 0.55B
SDOW ProShares UltraPro Short Dow30

+35.60 (+299.66%)

USD 0.32B
YANG Direxion Daily FTSE China Bear..

-11.76 (-16.25%)

USD 0.17B
DOG ProShares Short Dow30

N/A

USD 0.17B
RWM ProShares Short Russell2000

+0.07 (+0.40%)

USD 0.16B
SPDN Direxion Daily S&P 500® Bear ..

-0.08 (-0.73%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2,641.32% 38% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,641.32% 38% F 99% N/A
Trailing 12 Months  
Capital Gain 2,212.87% 38% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,212.87% 38% F 98% N/A
Trailing 5 Years  
Capital Gain 712.32% 40% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 712.32% 40% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.57% 38% F 93% A
Dividend Return 46.62% 38% F 93% A
Total Return 1.05% 55% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 393.11% 62% D 3% F
Risk Adjusted Return 11.86% 38% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.